Lilly assumes development of Transition's diabetes drug candidate

06/19/2013 | Wall Street Journal, The

Eli Lilly and Co. is exercising a $7 million option to obtain all development and marketing rights to Transition Therapeutics' experimental type 2 diabetes drug TT-401. Transition could get around $240 million more in milestone fees plus royalties if the drug reaches market. "We look forward to continuing the development of TT-401, as it supports our strategy of offering a broad portfolio of therapies for people with diabetes," Lilly official David Moller said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ